GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
| Website: | www.glycomimetics.com |
| Email: | info@glycomimetics.com. |
| Main Phone: | +1 240 243-1201 |
| Address: | 9708 Medical Center Drive |
| Address 2: | Suite 1700 |
| State: | MD |
| City / Town: | Rockville |
| Country: | US |
| Postal Code: | 20850 |
| Exchange: | NSD |
| CEO: | Rachel K. King |
| Employees: | 57 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Global study to evaluate uproleselan in 380 patients with Relapsed/Refractory AML (Image: GlycoMimetics)
The biotech sector is a fast growing market opportunity for investors, especially those with a taste for high risk and long-term views. Biotechnology is the technological application of modifying
GlycoMimetics (GLYC) is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which
Each week, we tap the insight of Sam Stovall, Chief Equity Strategist for S&P Capital IQ, for his perspective on the current market.EQ: October is coming to a close, which means that investors
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
| Website: | www.glycomimetics.com |
| Email: | info@glycomimetics.com. |
| Main Phone: | +1 240 243-1201 |
| Address: | 9708 Medical Center Drive |
| Address 2: | Suite 1700 |
| State: | MD |
| City / Town: | Rockville |
| Country: | US |
| Postal Code: | 20850 |
| Exchange: | NSD |
| CEO: | Rachel K. King |
| Employees: | 57 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Global study to evaluate uproleselan in 380 patients with Relapsed/Refractory AML (Image: GlycoMimetics)
The biotech sector is a fast growing market opportunity for investors, especially those with a taste for high risk and long-term views. Biotechnology is the technological application of modifying
GlycoMimetics (GLYC) is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which
Each week, we tap the insight of Sam Stovall, Chief Equity Strategist for S&P Capital IQ, for his perspective on the current market.EQ: October is coming to a close, which means that investors
| Last Price 3.77 | Change $ -0.11 | Change % -2.84 | Tick N/A |
| Bid 3.77 | Bid Size 800.00 | Ask 3.78 | Ask Size 700.00 |
| Open 3.85 | High 3.92 | Low 3.76 | Prev Close 3.88 |
| Last Trade | Volume 348,034 | 52 Wk Hi 6.29 | 52 Wk Low 1.83 |
| Market Cap 180.3 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 47,828,831.00 | EPS (TTM) -1.13 | PE Ratio -3.30 | Exchange NSD |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 23 | 25 |
| Number of Buys | 8 | 8 |
| Number of Sells | 15 | 17 |
| Net Activity | -42702 | -46702 |
| Last 10 Buys | Shares |
|---|---|
| Daniel M. Junius | 1,000 |
| Mark A. Goldberg | 1,000 |
| Michael A. Henos | 1,000 |
| Michael A. Henos | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Brian M. Hahn | 1,000 |
| Peter J. Barris | 1,000 |
| Peter J. Barris | 1,000 |
| M. James Barrett | 1,000 |
| Sandell D Scott | 1,000 |
| Sandell D Scott | 1,000 |
| M. James Barrett | 1,000 |
| Helen M. Thackray | 1,000 |
| Helen M. Thackray | 1,000 |
| Helen M. Thackray | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 35 | 35 | 35 | 35 |
| Low Target Price Estimate | 21 | 21 | 21 | 21 |
| Mean Target Price Estimate | 28.25 | 28.25 | 28.25 | 28.25 |
| Standard Deviation | 6.4 | 6.4 | 6.4 | 6.4 |
| Date of Most Recent Estimate | 05/31/18 | 05/03/18 | 05/03/18 | 05/31/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-24 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-11 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait